1. sayfa ve
Tekrarlanan kayıtlar tek bir kaynakta birleştirilmektedir.
1
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Cannabinoids and COVID-19 involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the
COVID 19 pandemia. covid-19
2
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Stand on the Same Side Against Covid – 19 Clinical Management of Covid-19 Covid-19
3
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Pharmacogenomics of COVID-19 therapies Abstract A new global pandemic of coronavirus disease 2019 (
COVID-
19) has resulted in high mortality and morbidity. In conclusion, although direct evidence in
COVID-
19 patients is lacking, we identified potential actionable genetic markers in
COVID-
19 therapies. Clinical studies in
COVID-
19 patients are deemed warranted to assess potential roles of these markers.
4
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Francesco Violi
,
Alessandra Oliva
,
Roberto Cangemi
,
Giancarlo Ceccarelli
,
Pasquale Pignatelli
,
Roberto Carnevale
,
Vittoria Cammisotto
,
Miriam Lichtner
,
Francesco Alessandri
,
Massimiliano De Angelis
,
Maria Claudia Miele
,
Gabriella D'Ettorre
,
Franco Ruberto
,
Mario Venditti
,
Francesco Pugliese
,
Claudio Maria Mastroianni
Yıl :
2020
Nox2 activation in Covid-19 RNA viruses may activate Nox2, but it is unknown if this occurs in coronavirus 2019(
Covid-
19). values were higher in
Covid-
19 patients versus controls and in severe versus non severe
Covid-
19. Oxidative stress by Nox2 activation is associated severe disease and thrombotic events in
Covid-
19 patients. Covid-19
5
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Pharmaceutical industry before COVID-19
6
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19 in hypertensive people COVID-
19 is an infectious disease caused by the SARS-CoV-2 coronavirus that affects people in advanced ages of life, patients with immunodepression and With this work we wanted to update the knowledge on the
COVID-
19 serious condition level in hypertensive patients and its association with the consumption covid-19
7
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19 Usurps Host Regulatory Networks Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (
COVID-
19). Certain characteristic
COVID-associated skin, sensory, and central nervous system manifestations may also be linked to viral activation of the RAAS, complement COVID-19
8
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID-19 and molecular hydrogen inhalation
9
Dergi Makalesi

Dergi Makalesi

Kaynak
1:
Kaynak
2:
Yazar(lar) :
Yıl :
2020
Can COVID-19 present unusual GI symptoms? COVID-19
10
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology
Yıl :
2020
Inhaled NO and COVID‐19
11
Dergi Makalesi

Dergi Makalesi

Kaynak
1:
Kaynak
2:
Dergi:
Yazar(lar) :
Yıl :
2020
Potential of Flavonoid-Inspired Phytomedicines against COVID-19 Here, we report on flavonoid phytomedicines with potential for development into prophylactics or therapeutics against coronavirus disease 2019 (
COVID-
19 spike protein, helicase, and protease sites on the ACE2 receptor used by the severe acute respiratory syndrome coronavirus 2 to infect cells and cause
COVID -
19. COVID-19
12
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Pharmacist's perspective on HCQ treatment of COVID‐19
13
Dergi Makalesi

Dergi Makalesi

Kaynak
1:
Kaynak
2:
Yazar(lar) :
Yıl :
2020
COVID-19 and RAS: Unravelling an Unclear Relationship angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (
COVID -
19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting. COVID-19
14
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2020
Dental procedure aerosols and COVID-19
15
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2020
COVID-19, myocardial edema and dexamethasone Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the cause of coronavirus disease- 2019 (
COVID-
19) after emerging in china in late 2019 is The most common cause of death in patient with
COVID-
19 is the rapid progression of acute respiratory distress syndrome (ARDS) shortly after the beginning Remdisivir is the only FDA -approved antiviral agent for treatment of severe
COVID-
19.
16
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2020
Angiotensin receptor blockers and COVID-19 For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current
COVID-
19 Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for
COVID-
19 patients. COVID-19
17
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Prophylactic Recommendation for Healthcare Workers in COVID-19 Pandemic During
COVID-
19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. So we have to improve protection and plan additional arrangements against
COVID-
19. Finally, the rate and severity of
COVID-
19 infections are compared.
18
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients Methods: Severe
COVID-
19 patients with self-reported SLS were recruited at hospitalization discharge. Conclusion: The prevalence of SLS in severe
COVID-
19 patients appears to be lower than previously estimated in mild-to-moderate
COVID-
19 forms. Future comparative studies are needed to explore the predictive value of SLS for
COVID-
19 severity. COVID-19
19
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Sedating ventilated COVID-19 patients with inhalational anesthetic drugs
20
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Therapeutic status of hydroxychloroquine in COVID-19: A review In the present pandemic of coronavirus disease (
COVID)-2019, the drug is being repurposed, based on its in vitro evidence of efficacy against coronavirus -
19. In the current scenario, recommendations from Indian Council of Medical Research for use of HCQ in the prophylaxis of
COVID-
19 are being followed. covid-19
21
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19 and Diabetes: The Importance of Controlling RAGE COVID-19
22
Dergi Makalesi

Dergi Makalesi

Kaynak
:
Dergi:
Yayıncı:
Springer Nature
Yazar(lar) :
Konu :
Drug delivery, Nanoparticles, Virology
Yıl :
2020
Dexamethasone nanomedicines for COVID-19 Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-
COVID-
19 treatment efficacy by targeting
23
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Possible role of tryptophan and melatonin in COVID-19
24
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Pharmacology
Yıl :
2020
Covid‐19 and thymoquinone: Connecting the dots
25
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Analysis on herbal medicines utilized for treatment of COVID-19 As coronavirus disease 2019 (
COVID-
19) pandemic poses a substantial global public health threat, traditional Chinese medicine (TCM) was used in 91.50% A total of 166 modified herbal formulae consisting of 179 single herbal medicines were collected for treating
COVID-
19 in China. -
19. COVID-19
26
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients
27
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2020
COVID-19 and liver disease: An update Moreover, the pandemic has also negatively impacted patients with liver disease who have not contracted
COVID-
19, since the reallocation of human and material enfermedades hepáticas que no han adquirido la enfermedad, ya que la redistribución de los recursos humanos y materiales hacia la atención de pacientes con
COVID -
19, ha provocado una merma en su tratamiento, diagnóstico y seguimiento que a buen seguro tendrá consecuencias negativas en el futuro. COVID-19 COVID-19